Yonhap Infomax NewsFeb 17, 2025
Axsome Therapeutics' stock soars 55% in 2023, with Motley Fool recommending it as a buy amid patent settlement and strong sales growth prospects
#YonhapInfomax #AxsomeTherapeutics #StockSurge #PatentSettlement #SalesGrowth #MotleyFoolRecommendation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=51006
US Pharma-Biotech Firm Axsome's Stock Surges 55% This Year - 'Not Too Late to Buy'

Axsome Therapeutics' stock soars 55% in 2023, with Motley Fool recommending it as a buy amid patent settlement and strong sales growth prospects

Yonhap Infomax